Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
A Retrospective Cohort Study Of Coagulation Function In Patients With Liver Cirrhosis Receiving Cefoperazone/sulbactam With And Without Vitamin K1 Supplementation.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
A Retrospective Cohort Study Of Coagulation Function In Patients With Liver Cirrhosis Receiving Cefoperazone/sulbactam With And Without Vitamin K1 Supplementation.

Related Experiment Video

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

A retrospective cohort study of coagulation function in patients with liver cirrhosis receiving cefoperazone/sulbactam with and without vitamin K1 supplementation.

Jianmo Liu¹, Jingyang Xiao², HongFei Wu³

¹Department of Science and Technology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.

International Journal of Clinical Pharmacy

|September 13, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Keywords:

Cefoperazone/sulbactam Coagulation disorder Liver cirrhosis Vitamin K1

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Related Experiment Videos

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Cefoperazone/sulbactam may increase coagulation risks in cirrhosis patients. Prophylactic vitamin K1 effectively mitigates these risks, including prothrombin time prolongation and general coagulation disorders.

Area of Science:

Pharmacology
Hepatology
Coagulation Science

Background:

Cefoperazone/sulbactam is a common antibiotic for infections in patients with cirrhosis.
Cirrhosis patients are susceptible to coagulation disorders.
The impact of cefoperazone/sulbactam on coagulation in cirrhosis requires investigation.

Purpose of the Study:

To determine the effect of cefoperazone/sulbactam on coagulation parameters in cirrhotic patients.
To evaluate the efficacy of vitamin K1 supplementation in preventing cefoperazone/sulbactam-induced coagulation abnormalities.

Main Methods:

Retrospective cohort study of 217 cirrhotic patients treated with cefoperazone/sulbactam.
Comparison between patients receiving vitamin K1 supplementation (n=108) and those who did not (n=109).

Propensity score matching (PSM) and SHapley additive exPlanations (SHAP) model were utilized.

Main Results:

Patients not receiving vitamin K1 showed significantly prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT) post-treatment.
The vitamin K1 group had minimal changes in PT and thrombin time, with only a slight aPTT increase.
Vitamin K1 supplementation significantly reduced the risk of PT prolongation (OR: 0.211) and coagulation disorders (OR: 0.257) compared to no supplementation.

Conclusions:

Cefoperazone/sulbactam administration is associated with an increased risk of prothrombin time prolongation and coagulation disorders in cirrhotic patients.
Prophylactic vitamin K1 administration is effective in reducing the incidence of these cefoperazone/sulbactam-induced coagulation abnormalities.
Vitamin K1 supplementation is a viable strategy to manage coagulation risks in cirrhotic patients receiving cefoperazone/sulbactam.